KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Enterprise Value (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Enterprise Value data on record, last reported at -$5.5 billion in Q4 2025.

  • For Q4 2025, Enterprise Value rose 39.12% year-over-year to -$5.5 billion; the TTM value through Sep 2025 reached -$8.4 billion, up 13.81%, while the annual FY2025 figure was -$5.5 billion, 39.12% up from the prior year.
  • Enterprise Value reached -$5.5 billion in Q4 2025 per REGN's latest filing, up from -$8.4 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$3.5 billion in Q1 2021 and bottomed at -$10.8 billion in Q4 2023.
  • Average Enterprise Value over 5 years is -$7.9 billion, with a median of -$8.3 billion recorded in 2025.
  • Peak YoY movement for Enterprise Value: crashed 101.23% in 2022, then skyrocketed 39.12% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$5.8 billion in 2021, then crashed by 33.77% to -$7.7 billion in 2022, then plummeted by 40.07% to -$10.8 billion in 2023, then grew by 16.9% to -$9.0 billion in 2024, then surged by 39.12% to -$5.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$5.5 billion in Q4 2025, -$8.4 billion in Q3 2025, and -$7.5 billion in Q2 2025.